Status: Recruiting
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.
Participants needed: 250
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Damora TherapeuticsUpdated: Oct 7, 2026Locations: 4
Eligibility criteria
Signed informed consent, which includes compliance with the requirements and res... [+3]
Presence of any malignancy unless participant has been disease free for at least... [+6]